earnings
confidence high
sentiment positive
materiality 0.80
Amgen Q3 2024 revenue $8.5B (+23%), GAAP EPS $5.22 (+62%), non-GAAP EPS $5.58 (+13%)
AMGEN INC
2024-Q3 EPS reported
$6.40
revenue$24,338,000,000
- Total revenues $8.5B (+23% YoY); product sales grew 24% on 29% volume growth.
- GAAP EPS $5.22 (+62%); non-GAAP EPS $5.58 (+13%).
- Free cash flow $3.3B vs $2.5B in Q3 2023.
- Rare disease portfolio contributed $1.2B in sales; 10 products had double-digit growth.
- Non-GAAP operating income $4.0B; operating margin 49.6% (down 2.4 ppt).